Association of Sodium-Glucose Cotransporter-2 Inhibitors With Reduced Hepatocellular Carcinoma Risk in Patients With Type 2 Diabetes
- 16 December 2025
- journal article
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 121 (9) , 2253-2262
Abstract
INTRODUCTION: Sodium-glucose cotransporter-2 inhibitors (SGLT2is) are widely prescribed for type 2 diabetes mellitus (T2DM) and may confer hepatoprotective effects. This study investigated their association with hepatocellular carcinoma (HCC) risk compared with other antidiabetic medications. METHODS: We conducted a retrospective cohort study using the electronic health records from Mass General Brigham (Boston, USA) and Asan Medical Center (Seoul, Korea) from 2013 to 2024. Adults with T2DM newly initiating SGLT2i, dipeptidyl peptidase-4 inhibitor (DPP4i), glucagon-like peptide-1 receptor agonist (GLP-1RA), or sulfonylureas were included. A 6-month landmark analysis was used to minimize early event bias. Inverse probability weighting combined with Fine-Gray competing risk models estimated subdistribution hazard ratios (SHRs) for incident HCC, accounting for transplant and death as competing events. RESULTS: After weighting, data from 6,733 SGLT2i, 4,495 GLP-1RA, 23,229 DPP4i, and 17,034 sulfonylurea initiators were analyzed. Over a median follow-up of 3.9 years (277,155 person-years), 623 HCC cases occurred. SGLT2i use was associated with significantly lower HCC risk vs sulfonylureas (SHR 0.44, 95% confidence interval [CI]: 0.25–0.79) and DPP4i (SHR 0.53, 95% CI: 0.30–0.93). The comparison with GLP-1RA showed comparable risk (SHR 0.87, 95% CI: 0.40–1.91). Subgroup analyses demonstrated consistent protective associations of SGLT2i in patients aged 65 years and younger, men, and those with chronic liver disease. Sensitivity analyses, including 12-month landmark analysis and adjustments for additional confounders, confirmed robustness of findings. DISCUSSION: SGLT2 inhibitor therapy was associated with reduced risk of HCC compared with DPP4 inhibitors and sulfonylureas, supporting their potential chemopreventive role in patients with T2DM.Keywords
Funding Information
- NIH (R01 CA255621)
- NIH (U01 CA288375)
This publication has 27 references indexed in Scilit:
- SGLT2 inhibitor empagliflozin downregulates miRNA-34a-5p and targets GREM2 to inactivate hepatic stellate cells and ameliorate non-alcoholic fatty liver disease-associated fibrosisMetabolism, 2023
- Sodium-glucose Cotransporter-2 Inhibitors and Risk of Hepatocellular Carcinoma Among Patients With Type 2 DiabetesClinical Gastroenterology and Hepatology, 2023
- SGLT2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trialsThe Lancet, 2022
- Efficacy of peroxisome proliferator-activated receptor agonists, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors for treatment of non-alcoholic fatty liver disease: a systematic reviewThe Lancet Gastroenterology & Hepatology, 2022
- Prevention of NAFLD-associated HCC: Role of lifestyle and chemopreventionJournal of Hepatology, 2021
- The complex link between NAFLD and type 2 diabetes mellitus — mechanisms and treatmentsNature Reviews Gastroenterology & Hepatology, 2021
- Canagliflozin inhibits growth of hepatocellular carcinoma via blocking glucose-influx-induced β-catenin activationCell Death & Disease, 2019
- The Epidemiology of Hepatocellular Carcinoma in the USACurrent Gastroenterology Reports, 2019
- AMPK Re-Activation Suppresses Hepatic Steatosis but its Downregulation Does Not Promote Fatty Liver DevelopmentEBioMedicine, 2018
- FIB-4Hepatology, 2007